30 results about "Blood markers" patented technology

An introducer having a sheath, a guide rod, and at least two wire stabilization guides being elongated members, at least a portion of which extend from an end of the sheath. The portions of the wire stabilization guides include a retention device formed on the portion of the wire stabilization guides that extend from the end of the sheath. The retention device is adapted to selectively expand outwardly, stabilizing the sheath relative to a wound site. The guide rod may be provided with one or more blood marking lumen, having a distal port, for identifying the depth of insertion into an artery or vein based on the presence or absence of pressurized blood in the lumen.

The present invention is related to methods of early diagnosis of ovarian cancer in a patient by determining serum levels of blood markers using a novel LabMAP™ technology (Luminex Corp., Austin, Tex.), which allows for simultaneous measurement of the blood markers in serum. The panel of blood markers offers extremely high predictive power for discrimination of ovarian cancer from both healthy control patients and from patients with benign pelvic / ovarian tumors. The methods of the present invention allow for rapid, early diagnosis of ovarian cancer with extremely high sensitivity and specificity to be clinically useful in disease diagnosis.

The present invention provides methods and materials related to the detection of colorectal neoplasm-specific markers in or associated with a subject's stool sample. In particular, the present invention provides methods and materials for identifying mammals having a colorectal neoplasm by detecting the presence of exfoliated epithelial markers (e.g., human DNA, tumor associated gene alterations, tumor associated proteins) and blood markers (e.g., homoglobin, serum proteins) in a stool sample obtained from the mammal.

The invention discloses a blood marker for diagnosing hepatic fibrosis and early cirrhosis. The blood marker refers to galectin 3. The concentration of the galectin 3 in the blood is analyzed by using the blood marker through enzyme linked immune reaction so as to analyze and evaluate hepatic fibrosis and early cirrhosis. By using the blood as the detection sample, early diagnosis on hepatic fibrosis and early cirrhosis can be achieved conveniently and rapidly.

The invention discloses a blood marker-based intelligent recognition system for an artificial neural network, belongs to the field of clinical laboratory diagnosis and artificial intelligence subjects, and relates to an artificial intelligent recognition system employing blood metabolite information. The system comprises two parts, namely a hardware system and a software system, wherein the hardware system is a metabolite data collection module of blood samples. According to the blood marker-based intelligent recognition system, whether one sample is from a patient with a kidney cancer or not can be recognized by the system according to the content of 2-4 metabolites in human blood, so that the prediction accuracy is high; and the result can provide a reference for early screening, diagnosis and treatment of the kidney cancer.

The invention discloses a peripheral blood methylation gene and IDH1 combined detection and diagnosis model for lung cancer. The invention provides application of methylated SHOX2 gene, methylated PTGER4 gene and IDH1 protein as markers in preparation of products for diagnosis or auxiliary diagnosis of lung cancer, and constructs a three-marker combined lung cancer diagnosis model. Experiments prove that: compared with an incorporated single factor, the diagnosis efficiency of the combined diagnosis model is remarkably enhanced. Therefore, the diagnosis efficiency of the lung cancer can be improved by combined detection blood markers.

There is provided a method where a feces occult blood test with a good precision is possible regardless of the sampling precision of feces. The above-mentioned method is achieved when the feces amount is corrected by an index being able to reduce the amount of the sampled feces to be tested in the measurement of hemoglobin and / or transferrin which are / is marker (s) for feces occult blood. Thus, together with the measurement of the feces occult blood marker, a signal obtained by the optical measurement of a suspension of the feces to be tested and / or the amount of the indigenous substances in the feces to be tested being able to be the above index and then the measured value of the feces occult blood marker is reduced using the measured value of the said index as a control whereby the above object is achieved.

The invention relates to the field of biological information, and discloses a method for predicting age by using a blood marker, which comprises the following four steps of: collecting blood marker data, preprocessing the data, establishing and evaluating a model and testing the model. Compared with other methods and markers, the method has the advantages that the blood marker serves as an evaluation object of the physiological age, the individual aging condition can be reflected more comprehensively, the aging level can be explained more comprehensively, meanwhile, the selected blood marker is predicted through the machine learning model, the process is more intelligent, and the result is more accurate; the selected blood marker, namely a blood biochemical index, is the most common indexin clinical and physical examination institutions, and is low in acquisition difficulty, low in cost and high in interpretation degree.

There is provided a method where a feces occult blood test with a good precision is possible regardless of the sampling precision of feces. The above-mentioned method is achieved when the feces amount is corrected by an index being able to reduce the amount of the sampled feces to be tested in the measurement of hemoglobin and / or transferrin which are / is marker (s) for feces occult blood. Thus, together with the measurement of the feces occult blood marker, a signal obtained by the optical measurement of a suspension of the feces to be tested and / or the amount of the indigenous substances in the feces to be tested being able to be the above index and then the measured value of the feces occult blood marker is reduced using the measured value of the said index as a control whereby the above object is achieved.

The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient.The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.

The invention discloses an information prompting method and a mobile terminal so that the user can be warned to pay attention to the own health better when using a mobile terminal. The method comprises the following steps that: after a target user is detected to operate a mobile terminal, blood indicator data of the target user are collected; the blood indicator data are compared with preset healthy blood indicator data of the target user; and when the comparison result meets a non-health condition, the mobile terminal carries out health information prompting.

The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods.

The invention relates to the field of biological information, and discloses a method for predicting gender by using a blood marker. The method comprises the following four steps of: collecting blood marker data, preprocessing the data, establishing and evaluating a model and testing the model. Compared with other methods and markers, the selected blood marker, namely a blood biochemical index, isthe most common index in clinical and physical examination institutions, the acquisition difficulty is low, the cost is low, and meanwhile, a machine learning model is used for calculating the selected blood marker, so that the process is more intelligent, and the result is more accurate.

The invention discloses a P16-based lung cancer postoperative comprehensive rehabilitation management method, which comprises a theoretical analysis module, a system establishment module, a case analysis module and PG-SGA nutrition assessment. The theoretical analysis module comprises NSCLC blood marker screening, a nutrition evaluation model and intervention measures, a physical strength evaluation model and intervention measures, a psychological evaluation model and intervention measures, and a traditional Chinese medicine constitution evaluation model and intervention measures, and the NSCLC blood marker screening comprises Meta-based NSCLC blood marker analysis and MDR-based blood marker screening. The nutrition evaluation model and the intervention measure adopt an FG-SGA evaluation model, and the physical power evaluation model and the intervention measure adopt an ECOG evaluation model. According to the P16-based lung cancer postoperative comprehensive rehabilitation management method, after a patient is discharged from a hospital, the patient can evaluate personal nutrition, psychology, physical strength and other conditions anytime and anywhere through a mobile phone APP, and professional and normative intervention measures are obtained according to personal evaluation results without extra expenditure.

The invention provides a tumor blood marker and an application thereof and particularly provides an application of a reagent for detecting GAPDH (glyceraldehyde 3-phosphate dehydrogenase) in a blood sample to preparation of composition for tumor screening, tumor risk assessment of a subject, tumor progression stage division, tumor curative effect identification and / or detection of tumor progression risk analysis. The invention further provides a kit and a detection method for GAPDH concentration of the blood sample.

The present invention relates to a composite marker for diagnosis of diabetic retinopathy and a use thereof and, more particularly, to a composite marker, for diagnosis of diabetic retinopathy, comprising two or more blood markers specific for diagnosis of diabetic retinopathy and thus having an improved diagnostic performance. In addition, the present invention relates to a composition for diagnosis of diabetic retinopathy, a diagnostic kit, and a method for providing information necessary for diagnosing diabetic retinopathy, each of which uses the composite marker. The composite marker for diagnosis of diabetic retinopathy of the present invention was found to be superior to combinations of other markers in terms of sensitivity and diagnosis performance and to exhibit a high diagnostic potential for initial diabetic retinopathy, as analyzed for combinations between protein quantitation values of the composite marker and fundamental clinical information. In addition, the composite biomarker of the present invention does not use blood proteins for biopsy, but can conveniently perform analysis by means of patient plasma and thus can be advantageously applied to the early diagnosis of diabetic retinopathy.

The invention discloses a multiplex detection kit for neonatal disease screening and a preparation method and a use method thereof. The multiplex detection kit comprises a buffer solution, at least two reaction cups, acridinium ester marker microspheres, a calibration product, a quality control product, an excitation solution, a concentrated washing solution and a hemolytic agent, the reaction cup is a micropore of which the inner surface is coated with a target antibody or antigen conjugate; the target antibody or antigen conjugate is an anti-TSH antibody protein, thyroxine T4 coupled bovine serum albumin, 17 alpha-hydroxyprogesterone coupled bovine serum albumin and an anti-GAA antibody protein. According to the invention, one kit is used for combined screening of multiple (2-8) blood markers, so that the preparation work is greatly simplified, errors caused by manual operation are reduced, and the working efficiency is improved; the high performance of quantitative detection is ensured by applying a chemiluminescence labeling immunoassay technology and a fluorescence analysis method which take acridinium ester as a marker.

The invention provides a kit for joint detection based on microspheres with different fluorescence intensities. The kit comprises a microsphere reagent, and a labeled second antibody or antigen; the microsphere reagent is N microspheres with the same diameter and different fluorescence intensity codes, the surfaces of the N microspheres are correspondingly coated with first antibodies or antigens of N blood markers, and N is an integer between 2 and 5; and the labeled second antibody or antigen comprises N second antibodies or antigens of blood markers, fluorescein is labeled on the second antibodies or antigens, and the binding sites of the first antibody or antigen and the corresponding antigens or antibodies and the binding sites of the second antibodies or antigens and the corresponding antigens or antibodies are different. The invention also relates to a method for joint detection based on microspheres with different fluorescence intensities. The kit provided by the invention can realize specific detection of five pathogen antigens / antibodies in blood transfusion through one-time reaction, and the detection process is simple, convenient and accurate.

The present invention relates to a composite marker for diagnosis of age related macular degeneration (AMD) and a use of same and, more specifically, to a composite markers for diagnosis of age related macular degeneration, which consists of two or more blood markers specific to diagnosis of age related macular degeneration and has improved diagnostic performance. In addition, the present invention relates to a composition for diagnosis of age related macular degeneration, a diagnostic kit, and a method for providing information necessary for diagnosing age related macular degeneration, each of which uses the composite marker. The composite marker for diagnosis of age related macular degeneration of the present invention was found to be superior to combinations of other markers in terms of sensitivity and diagnosis performance and to exhibit a high diagnostic potential for both initial and late macular degeneration, as analyzed for combinations between protein quantitation values of the composite marker and fundamental clinical information. In addition, the composite marker of the present invention does not use blood proteins for biopsy, but can conveniently perform analysis using patient plasma and as such, can be advantageously applied to the early diagnosis of age related macular degeneration.

The invention discloses an application of GSK-3beta as a blood marker in the preparation of a diagnostic reagent for mental disorders, especially autism spectrum disorders (ASD). GSK-3beta can be usedas an ASD early-diagnosis reagent, and a detection time window is 0-3 months for newborns. The non-invasive auxiliary diagnosis of ASD can be carried out by only using a small amount of blood sample,the large-scale infant ASD screening is facilitated, and early discovery, early intervention and early treatment of ASD are facilitated.

The invention discloses a punching device for blood standard card sampling, comprising: a bracket; a driving part, the driving part is installed on the bracket; a buffer part, the buffer part includes a buffer plate and a buffer spring, and the buffer plate can move along the Z axis Installed on one end of the bracket, the buffer spring is installed between the buffer plate and the bracket; and the tine, the tine is fixed on the buffer plate, the tine can move along the Z axis and is placed on the bracket, the tine The extruding end away from the needle tip is located in the bracket, and the driving part is used to drive the perforating needle to move along the Z axis to punch holes. Since the driving part is installed on the bracket, the driving part can be used to drive the punching to punch holes for the blood label card, realizing automatic punching, improving the efficiency and accuracy of punching, and the punching needle is installed on the buffer plate, and the buffer plate is connected with the punching plate. A buffer spring is installed between the brackets, and the buffer spring can effectively relieve the impact force when the tine is punched, play the role of buffering and shock absorption, and improve the service life of the tine.

The invention provides a laboratory diagnosis blood marker for liver fibrosis caused by hepatitis B virus, and belongs to the technical field of diagnostics. The marker provided by the invention is highly expressed in plasma of a patient with liver fibrosis, and the expression level is related to the severity of liver fibrosis. The marker has excellent diagnostic value when used for detection, so that early diagnosis and early treatment of hepatitis B liver fibrosis are realized.

The invention provides a device for detecting diagnostic blood markers as early as half an hour upon an acute myocardial infarction symptoms onset.

Presented herein are methods of identifying a subject who has, or is at risk of developing Alzheimer's disease comprising determining a presence or amount of 2-aminoethyl dihydrogen phosphate or taurine in the blood, or a blood product, obtained from the subject. Also presented herein are method of preventing, treating or delaying the onset of Alzheimer's disease.

The present invention provides methods for early diagnosis of amyotrophic lateral sclerosis (ALS) and for determining the efficacy of a treatment for ALS in an ALS patient, i.e., monitoring ALS progression, utilizing cellular blood markers; as well as kits for carrying out these methods.

The present invention relates to a method for detecting bowel transplant rejection.The detection method according to the invention is a method for the in vitro detection of bowel transplant rejection comprising steps for measuring the concentration at markers in a fluid sample, calculating the difference for each marker with a reference concentration, comparing for each marker the difference with a discriminatory threshold variation and assigning a score.The present invention is particularly applicable in the medical field, more specifically in the field of transplantations and transplant rejection detection.

The invention discloses a system for predicting lignified pectoral muscle of broiler chicken through blood markers and application, a regression equation for predicting the lignified pectoral muscle of the broiler chicken is established through the blood markers, whether the pectoral muscle of the broiler chicken is lignified or not is predicted according to the regression equation, and the blood markers comprise any one or three of the content of pO2, the content of sO2 and the content of pCO2 in blood. The system provided by the invention comprises a data acquisition module used for acquiring the content of blood markers in broiler chicken sample blood; the data processing module is used for substituting the received blood marker content data in the data acquisition module into a regression equation for data processing to obtain a regression value; the data studying and judging module is used for receiving the regression value obtained by processing of the data processing module and studying and judging whether the breast muscle of the meat chicken is lignified or not; and the output module is used for outputting the research and judgment result and displaying the research and judgment result on the processor.